|
Because they are pursuing high-risk research on investor capital, biotechnology companies typically cannot offer the stability and salaries of well-established firms with steady revenues. To attract the top scientific and business talent they need to succeed, biotech companies usually include stock options in compensation packages for both top executives and rank-and-file employees.
As a member of the International Employee Stock Options Coalition, BIO is urging Congress to block the measure. Expensing would discourage the offering of options, and many of the accounting options for expensing are inappropriate for emerging companies with volatile stocks.
Comments by CytImmune Sciences Inc. President and CEO, Lawrence Tamarkin
Before the Internal Revenue Service on Private Company Stock Options Valuation Reform (January 25, 2006)
Read the Comments (42 KB PDF)
Comments Intronn President and CEO, Gary McGarrity, Ph.D.
Before the Internal Revenue Service on Private Company Stock Options Valuation Reform (January 25, 2006)
Read the Comments (45 KB PDF)
Comments on Proposed Regulations for Section 409A: Application to Stock Options
To IRS Commissioner Mark W. Everson (January 3, 2006)
Read the Comments (43 KB PDF)
Fact Sheet
Why Employee Stock Options Should Not Be Expensed (May 12, 2003)
Read the Fact Sheet
SEC Guidelines on Stock Option Expensing
Complex Technical Hurdles Faced by U.S. Companies in Implementing SFAS 123R By June 15, 2005 (April 1, 2005)
Read the Talking Points
BIO Letter
Letter to Speaker Hastert expressing opposition to the FASB proposal (July 19, 2004)
Read the Letter (856 KB PDF)
Legislative Summary
S. 1890 and HR 3574, The Stock Options Accounting Reform Act of 2003
Read the Summary
Press Release
House Passes Reasonable Stock-option Accounting Reform (7/20/2004)
Read the Press Release
Testimony
Before the Energy and Commerce Subcommittee on Commerce, Trade and Consumer Protection, regarding FASB proposal to mandate stock option expensing.
Read the Testimony
Comments
To FASB regarding Share-Based Payment, an amendment of FASB Statements No. 123 and 95 (June 26, 2004)
Read the Comments
Stock Options Archive
Older materials on this subject are available in our archive.
Browse the Archive
| 
